Notice of extraordinary general meeting in Nanexa AB (publ)

The shareholders in Nanexa AB (publ), reg.no 556833-0285 (the "Company") are hereby given notice that an extraordinary general meeting will be held on Monday, 14 December 2026 at 15: 00 at the Company's premises at Virdings Allé 2, Uppsala, Sweden.

Right to participate in the general meeting

Shareholders who wish to exercise their voting rights at the general meeting must:

- be recorded in the share register in their own names (not nominee-registered) maintained by Euroclear Nordics AB on Friday, 4 December 2026 (the record date); and
- notify their intention to attend the general meeting no later than Tuesday, 8 December 2026 by mail to Nanexa AB, Virdings Allé 2, 754 50 Uppsala, by e-mail to info@nanexa.se or by telephone on 018 - 100 300.

When notifying, provide the shareholder's name, personal or corporate identification number, address, telephone number, shareholding, and, if applicable, details of any representatives or proxies.

Nominee-registered shares
Shareholders whose shares are nominee-registered must, in order to exercise the right to vote and participate in the general meeting, temporarily register their shares in their own names (so-called voting rights registration) with Euroclear Nordics AB so that the shareholder is included in the share register kept by Euroclear Nordics AB as per the record date, i.e. Friday 4 December 2026. Voting rights registration requested by shareholders in such time that the relevant nominee has completed the registration no later than Tuesday, 8 December 2026 will be considered in the preparation of the share register. This means that shareholders who wish to temporarily register their shares in their own names must make such a request to their nominees well in advance of this date.

Proxy
Shareholders represented by proxy must submit a dated power of attorney. The power of attorney may not be valid for a period longer than five years from its issuance. The original power of attorney and certificate of registration and other authorization documents evidencing the right to act on behalf of a legal person should be submitted to the Company by post at the address mentioned above in due time prior to the general meeting. The Company provides a proxy form on request and on the Company's website, www.nanexa.com.

Number of shares and votes

At the time of the issue of this notice, the total number of shares and votes in the Company amounts to 196,288,097.

Proposed agenda

1. Opening of the meeting and election of the chairman for the meeting
2. Establishment and approval of the voting list
3. Election of one or two persons to attest the minutes
4. Determination as to whether the meeting has been duly convened
5. Approval of the agenda
6. Determination of the number of members of the board of directors
7. Election of the board of directors
8. Determination of remuneration to the board of directors
9. Closing of the meeting

Resolution proposals

Item 1 – Opening of the meeting and election of the chairman for the meeting

It is proposed that attorney-at-law Gunnar Mattsson is appointed as chairman of the general meeting.

Item 6 – Determination of the number of members of the board of directors

The nomination committee proposes that the board of directors shall consist of six (6) members without deputy members. This represents an increase from the current five (5) members.

Item 7 – Election of the board of directors

The nomination committee proposes the election of Per Falk as a new ordinary member of the board of directors for the period until the next annual general meeting. Provided that Per Falk is elected at the general meeting, the Company's board of directors will therefore consist of Göran Ando, Birgit Stattin Norinder, Richard Davis, Jakob Dynnes Hansen, Hanna Tilus and Per Falk for the period until the next annual general meeting.

About Per Falk

Per Falk, MD, PhD, has extensive experience in the pharmaceutical industry, with a unique background in both drug development and commercial operations. He previously served as Senior Vice President of Biopharmaceutical Research at Novo Nordisk and as Head of R&D and subsequently CEO of Ferring Pharmaceuticals. He is currently CEO of GC Holdings, a dental technology company. Per Falk is independent in relation to the Company, its management and its major shareholders.

Item 8 – Determination of remuneration to the board of directors

The nomination committee proposes that remuneration shall be paid to the chairman of the board of directors in the amount of SEK 600,000 and to each of the other members who are not employed by the Company in the amount of SEK 400,000, calculated pro rata for the period from the extraordinary general meeting until the next ordinary annual general meeting. The

remuneration for the audit committee is proposed to remain unchanged, with SEK 100,000 to the chairman of the audit committee and SEK 50,000 to each of the other members of the audit committee.

The nomination committee further proposes that remuneration to the members of the existing board of directors for the period from the annual general meeting on May 12, 2026, until the extraordinary general meeting shall be paid pro rata for that period, based on the remuneration resolved upon at the annual general meeting on May 12, 2026, i.e. SEK 260,000 to the chairman of the board of directors and SEK 130,000 to each of the other members who are not employed by the Company.

If the general meeting resolves in accordance with items 6 and 7 above, the nomination committee proposes that Per Falk shall receive board remuneration proportionate to the remaining term of office until the next annual general meeting.

Processing of personal data
In connection with the general meeting, personal data will be processed in accordance with the Company's privacy policy, available on the Company's website www.nanexa.com.

Questions to the board of directors and the managing director
The board of directors and the CEO shall, if requested by any shareholder and if the board is of the opinion that it can be done without causing material harm to the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda or circumstances that may affect the assessment of the Company's financial situation.

Provision of documents
Documents pursuant to the Swedish Companies Act will be available at the Company and on the Company's website, www.nanexa.com, no later than 30 November 2026. The documents will also be sent free of charge to shareholders who so request and provide their postal or e-mail address.

Uppsala, November 2026

Nanexa AB (publ)

The Board of Directors

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se

The company's Certified Adviser is Tapper Partners AB.

About Nanexa AB (publ)

Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company's proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of 'super generic' formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others.
Nanexa develops its own products and also has collaboration agreements with several pharma companies, including the latest license and option agreement with Moderna.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Notice of extraordinary general meeting in Nanexa AB (publ)